Table 1 Sociodemographic and clinico-immunological characteristics at ART initiation by cohort, Arua, Uganda, 2006
Patient characteristics | M12 cohort | M24 cohort | ||
|---|---|---|---|---|
| Â | Eligible (N = 70) | Surveyed (N = 59) | Eligible (N = 32) | Surveyed (N = 27) |
Demographic factors | Â | Â | Â | Â |
   Girls (%) | 32 (45) | 28 (47.5) | 14 (44) | 11 (40.7) |
   Median age, years [IQR] | 5.4 [3.2 -8.2] | 5.6 [3.2-8.3] | 5.5 [4.2-7.7] | 5.1 [4.2-7.5] |
   Age group (%) |  |  |  |  |
12-35 months | 13 (18.6) | 12 (20.3) | 6 (18.8) | 5 (18.5) |
36-59 months | 19 (27.1) | 14 (23.7) | 6 (18.8) | 6 (22.2) |
5-14 years | 38 (54.3) | 33 (55.9) | 20 (62.4) | 16 (59.3) |
Treatment history | Â | Â | Â | Â |
   ARV naïve (%) | 67 (95.7) | 56 (94.9) | 31 (96.9) | 26 (96.3) |
   Median follow-up without ARVs, months [IQR] | 5.9 [3.5-11.1] | 6.9 [4.2-13.3] | 6.3 [1.7-12.0] | 6.4 [1.7-12.3] |
Clinical factors | Â | Â | Â | Â |
   Clinical stage (%) | n = 68 | n = 58 | n = 32 | n = 27 |
Stage 1/2 | 16 (23.6) | 13 (25.9) | 7 (21.9) | 5 (18.5) |
Stage 3 | 44 (63.2) | 36 (62.1) | 18 (56.2) | 15 (55.6) |
Stage 4 | 9 (13.2) | 7 (12.0) | 7 (21.9) | 7 (25.9) |
   Weight-for-height z-score | n = 62 | n = 52 | n = 29 | n = 25 |
Median [IQR] | -1.1 [-2.0 to -0.5] | -1.2 [-2.1 to -0.6] | -0.8 [-1.6 to -0.1] | -0.8 [-1.8 to -0.3] |
< -2 score (%) | 17 (27.4) | 15 (28.8) | 3 (10.3) | 3 (12.0) |
ART regimen (%) | Â | Â | Â | Â |
   AZT 3TC NVP | 54 (77.1) | 49 (83.1) | 25 (78.1) | 21 (77.8) |
   d4T 3TC NVP | 16 (22.9) | 10 (17.0) | 7 (21.9) | 6 (22.2) |
CD4 testing, median [IQR] | Â | Â | Â | Â |
   CD4 cell count a | n = 14 | n = 11 | n = 17 | n = 15 |
| Â | 190 [106-302] | 200 [166-302] | 70 [22-149] | 70 [20-152] |
   CD4% b | n = 12 | n = 10 | n = 2 | n = 2 |
| Â | 10 [8-14] | 11 [8-14] | 14 [10-17] | 13 [10-17] |